CD19 Surge: Multi-Billion-Dollar Deals Land as Field Pushes From Blood Cancers Into Autoimmune Disease

Over the past month, the CD19 space has kept heating up and expanded from hematologic malignancies into autoimmune disease. Simcere licensed its CD19 tri-specific antibody to Roche for 1.53 billion USD, and Abogen's mRNA-CD19 TCE went to Novartis in a deal worth up to 7.78 billion USD. An in vivo CAR-T study was published in NEJM, dual-target therapy showed strong data, and Bioray's allogeneic CD19 CAR-T entered a CDE pilot program for compassionate use.